The cancer-immunity cycle provides a framework to understand the series of events that
generate anti-cancer immune responses. It emphasizes the iterative nature of the response …

Chimeric antigen receptor (CAR) T cells have been approved for use in patients with B cell
malignancies or relapsed and/or refractory multiple myeloma, yet efficacy against most solid …

Pancreatic and colorectal cancers are often KRAS mutated and are incurable when tumor
DNA or protein persists or recurs after curative intent therapy. Cancer vaccine ELI-002 2P …

In the past decade, chimeric antigen receptor (CAR)-T cell therapy has emerged as a
promising immunotherapeutic approach for combating cancers, demonstrating remarkable …

Tap** into the innate immune system's power, nanovaccines can induce tumor-specific
immune responses, which is a promising strategy in cancer immunotherapy. However …

With the lifestyle change and environmental pollution, tumors have become one of the most
serious diseases that threaten human health. However, therapeutic and drug resistances …

New York-esophageal cancer 1 (NY-ESO-1) belongs to the cancer testis antigen (CTA)
family, and has been identified as one of the most immunogenic tumor-associated antigens …

Chimeric antigen receptor T cells (CAR-T) therapy has shown great potential in tumor
treatment. However, many factors impair the efficacy of CAR-T therapy, such as antigenic …

Therapeutic cancer vaccines have been a subject of research for several decades as
potential new weapons to tackle malignancies. Their goal is to induce a long-lasting and …

Suppression of chimeric antigen receptor-modified T (CAR-T) cells by the
immunosuppressive tumor microenvironment remains a major barrier to their efficacy …